바카라사이트 벳페어 publishes study on ‘amplified activated bone marrow infiltrating lymphocytes’ in international academic journal
- Published in the SCI-level international journal ‘Translation Oncology’ - In vitro culture boosts central memory T cells by 80%, maximizing sustained multiple myeloma killing efficacy - Development of BCMA CAR-MIL immunotherapy for multiple myeloma selected as a national project in June - 바카라사이트 벳페어 leads BCMA CAR-MIL immunotherapy development in the global market
[by Kang, In Hyo] 바카라사이트 벳페어, a company specializing in the development of anticancer immunotherapies, announced on August 1 the publication of a research paper in the SCI-level international journal Translational Oncology. The study details the tumor specificity and cytotoxic capacity of ex vivo expanded and activated bone marrow-infiltrating lymphocytes (MILs).
Through this publication, 바카라사이트 벳페어 has significantly reinforced the academic foundation for its BCMA (B-cell maturation antigen) CAR-MIL (chimeric antigen receptor-bone marrow-infiltrating lymphocyte) therapy for multiple myeloma, which was recently selected as a national novel drug development project. As a global leader in the research and development of BCMA CAR-MIL therapies for multiple myeloma, 바카라사이트 벳페어 secured its position in June with the selection of the project under the National New Drug Development Program.
According to the study, MILs isolated from patients with multiple myeloma were expanded, cultured, and activated in vitro. These 바카라사이트 벳페어s exhibited superior tumor specificity and cytotoxic activity compared to peripheral blood-derived T 바카라사이트 벳페어s. By day 14 of culture, the proportion of central memory T 바카라사이트 벳페어s increased to 80%, thereby maximizing tumor-targeting specificity. Concurrently, the presence of immunosuppressive 바카라사이트 벳페어s, such as myeloid-derived suppressor 바카라사이트 벳페어s (MDSCs) and regulatory T 바카라사이트 벳페어s, was significantly reduced, demonstrating potent cytotoxicity against autologous multiple myeloma 바카라사이트 벳페어s.
"The patient-tailored multiple myeloma treatment currently in development is characterized by an enrichment of central memory T cells possessing diverse tumor antigen profiles in the bone marrow microenvironment. In addition, these cells are engineered to express a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA) in multiple myeloma. We expect this approach to serve as a key to the treatment of hematologic malignancies, addressing the limitations of existing CAR-T cell therapies, such as insufficient tumor specificity and relapse due to immune evasion," stated Lee Je-jung, CEO of Vaxcellbio.